MDWD
MediWound Ltd.
$12.10
+0.00
(+0.00%)
Mkt Cap
158.99M
Volume
155,321
52W Range
11.84-19.7
Sector
Healthcare
Beta
0.14
EPS (TTM)
-1.60 USD
P/E Ratio
-8.79
Revenue (TTM)
11.86M USD
Rev Growth (5Y)
-4.9%
EPS Growth (5Y)
N/A
Company Description
MediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel, bio-therapeutic, and non-surgical solutions for tissue repair and regeneration in the United States, Germany, Italy, Spain, and internationally. The company markets NexoBrid, a biopharmaceutical product for the removal of eschar in patients with deep partial- and full-thickness thermal burns to burn centers and hospitals burn units. It also develops EscharEx, a bromelain-based, bioactive enzymatic therapy for the treatment of chronic wounds and other hard-to-heal wounds; and MW005, a topically applied biological product candidate to treat non-melanoma skin cancers. MediWound Ltd. was incorporated in 2000 and is headquartered in Yavne, Israel.
Track Record
Showing latest 4 periods • Swipe for more
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 16.96M | 20.22M | 18.69M | 26.50M | 23.76M | 21.76M | 31.79M | 3.40M | 2.50M | 1.56M | 601,000 | 259,000 |
| Net Income | (23.88M) | (30.22M) | (6.72M) | (19.60M) | (13.55M) | (9.20M) | 4.96M | (1.06M) | (22.15M) | (18.89M) | (22.09M) | (18.88M) |
| EPS | -2.10 | -3.03 | -0.75 | -3.93 | -3.48 | -2.38 | 1.26 | -0.28 | -6.64 | -6.05 | -7.13 | -6.65 |
| Free Cash Flow | (20.04M) | (19.90M) | (16.93M) | (12.44M) | (9.40M) | (7.82M) | 7.50M | (12.69M) | (17.53M) | (17.15M) | (20.01M) | (16.89M) |
| FCF / Share | -1.76 | -2.00 | -1.88 | -2.49 | -2.42 | -2.01 | 1.93 | -3.28 | -5.26 | -5.49 | -6.46 | -5.95 |
| Operating CF | (14.53M) | (13.62M) | (10.46M) | (11.88M) | (8.92M) | (6.89M) | 8.29M | (12.15M) | (16.45M) | (16.45M) | (19.60M) | (16.49M) |
| Total Assets | 86.25M | 73.50M | 66.46M | 50.02M | 19.74M | 31.07M | 40.59M | 35.28M | 44.13M | 35.76M | 52.52M | 71.12M |
| Total Debt | 8.15M | 6.93M | 6.35M | 846,000 | 1.39M | 1.74M | 2.01M | 0 | 0 | 0 | 0 | 0 |
| Cash & Equiv | 4.80M | 9.15M | 11.87M | 33.90M | 11.05M | 17.38M | 7.24M | 6.72M | 36.07M | 28.87M | 42.50M | 25.42M |
| Book Value | 43.63M | 31.15M | 31.59M | 10.91M | (4.58M) | 7.27M | 15.17M | 8.97M | 9.62M | 7.77M | 23.47M | 42.87M |
| Return on Equity | -0.55 | -0.97 | -0.21 | -1.80 | N/A | -1.26 | 0.33 | -0.12 | -2.30 | -2.43 | -0.94 | -0.44 |
| Metric | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 3.09M | 1.48M | 1.87M | 5.43M | 5.71M | 3.96M | 5.84M | 4.36M | 5.06M | 4.96M | 5.34M | 4.78M |
| Net Income | (7.39M) | (2.95M) | (7.18M) | (2.65M) | (13.32M) | (726,000) | (3.91M) | (10.28M) | (6.30M) | (9.73M) | (1.74M) | (2.20M) |
| EPS | -0.57 | -0.23 | -0.56 | -0.24 | -1.23 | -0.07 | -0.36 | -0.98 | -0.68 | -1.05 | -0.19 | -0.24 |
| Free Cash Flow | (10.06M) | (8.57M) | (5.47M) | (4.28M) | (6.80M) | (5.07M) | (2.44M) | (4.95M) | (6.64M) | (5.26M) | (4.82M) | (4.94M) |
| FCF / Share | -0.78 | -0.67 | -0.43 | -0.39 | -0.63 | -0.49 | -0.23 | -0.47 | -0.72 | -0.57 | -0.52 | -0.54 |
| Operating CF | (8.99M) | (6.75M) | (3.02M) | (3.24M) | (5.76M) | (4.11M) | (1.64M) | (3.76M) | (3.62M) | (4.00M) | (2.62M) | (3.25M) |
| Total Assets | 71.88M | 79.98M | 86.25M | 94.42M | 67.00M | 69.02M | 73.50M | 74.73M | 57.30M | 62.38M | 66.46M | 67.02M |
| Total Debt | 9.54M | 8.13M | 8.15M | 8.27M | 8.89M | 6.42M | 6.51M | 6.46M | 7.85M | 6.47M | 6.35M | 5.93M |
| Cash & Equiv | 4.34M | 44.65M | 4.80M | 59.09M | 1.06M | 38.27M | 9.15M | 45.56M | 3.79M | 35.57M | 11.87M | 9.28M |
| Book Value | 35.64M | 41.42M | 43.63M | 50.16M | 20.12M | 31.27M | 31.15M | 34.23M | 17.87M | 23.20M | 31.59M | 33.05M |
| Return on Equity | -0.21 | -0.07 | -0.16 | -0.05 | -0.66 | -0.02 | -0.13 | -0.30 | -0.35 | -0.42 | -0.06 | -0.07 |
MDWD News
Taysha Gene Therapies (NASDAQ:TSHA) versus MediWound (NASDAQ:MDWD) Head to Head Analysis
MediWound Awarded Additional $3.3 Million from U.S. Department of War to Advance Room-Temperature-Stable Formulation of NexoBrid®
Independent DSMB Recommends MediWound's EscharEx® Phase III VALUE Study Continue Without Modification
MediWound to Present at the H.C. Wainwright 28th Annual Global Investment Conference
MediWound Ltd. (MDWD) Q2 2026 Earnings Call Transcript
MediWound Q2 Earnings Call Highlights
MediWound (MDWD) Reports Q2 Loss, Beats Revenue Estimates
MediWound Reports Second Quarter 2026 Financial Results and Provides Corporate Update
MediWound to Report Second Quarter 2026 Financial Results
MediWound Ltd. (MDWD) Q1 2026 Earnings Call Transcript